EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer. EF5 may be effective in measuring oxygen in tumor tissue. Photosensitizing drugs such as motexafin lutetium are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. Knowing the level of oxygen in tumor tissue and the level of motexafin lutetium absorbed by tumors and normal tissue may help predict the effectiveness of anticancer therapy

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Motexafin lutetium

Criteria

Inclusion Criteria:

• Histologically confirmed or suspected diagnosis of 1 of the following:

• Intra-abdominal malignancy of 1 of the following types:

• Sarcoma

• Ovarian cancer

• Gastrointestinal malignancies, including, but not limited to, appendiceal cancer, colon cancer, or gastric cancer

• Non-small cell lung cancer

• Planning to undergo surgical resection of disease

• Disease has the propensity to spread to the peritoneal cavity (intra-abdominal malignancy patients)

• Performance status - ECOG 0-2

• WBC ≥ 2,000/mm^3

• Platelet count ≥ 100,000/mm^3

• Bilirubin < 1.5 mg/dL

• Creatinine normal

• Creatinine clearance ≥ 60 mL/min

• Body weight ≤ 130 kg

• No G6PD deficiency

• No porphyria

• No history of peripheral neuropathy ≥ grade 3

• Able to tolerate anesthesia and major surgery

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 1 month after study participation